ORGO Organogenesis Holdings (A)

MEDIA ALERT: Organogenesis Holdings Inc. (Nasdaq: ORGO) to Ring the Nasdaq Stock Market Closing Bell

MEDIA ALERT: Organogenesis Holdings Inc. (Nasdaq: ORGO) to Ring the Nasdaq Stock Market Closing Bell

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) --

What:

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Gary S. Gillheeney, Sr., President & CEO, will ring the Closing Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Friday, September 6, 2019 – 3:45 p.m. to 4:00 p.m. ET        

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit:

.

For photos from ceremonies and events, please visit:

For livestream of ceremonies and events, please visit:

For news tweets, please visit:

For exciting viral content and ceremony photos, please visit:

Webcast:

A live stream of the Nasdaq Closing Bell will be available at:

or

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to and click on the market close of your choice.

           

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit Information on our website is not part of this release.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to approximately 4,000 total listings with a market value of approximately $14 trillion. To learn more, visit: .

Organogenesis Holdings Inc. Media Contact:
Angelyn Lowe
781-774-9364
 

Nasdaq MarketSite Media Contact:
Bianca Fata
(646) 441-5073
 
EN
06/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million ...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2...

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m....

 PRESS RELEASE

Organogenesis Announces Initiation of Biologics License Application fo...

Organogenesis Announces Initiation of Biologics License Application for ReNu® Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administ...

 PRESS RELEASE

Organogenesis Announces Successful FDA Meeting and Plan to File BLA fo...

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administra...

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Summary: Net product revenue of $150.5 million for the third quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch